We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bruker (BRKR) Launches the MALDI Biotyper Sirius System
Read MoreHide Full Article
Bruker Corporation (BRKR - Free Report) launched the new MALDI Biotyper sirius system for all previously FDA-approved assays and research-use-only (RUO) MALDI Biotyper (MBT) reference libraries at the ASM Microbe Conference 2019. These reference libraries are used for near-universal, fast and cost-efficient microbial identification from cultures in microbiology. The launch is a milestone for Bruker in the field of assay research and clinical studies for fast antibiotic-resistance testing.
More About MALDI Biotyper Sirius
The MALDI Biotyper sirius supports novel negative-ion mode assay research and clinical studies in fast antibiotic-resistance testing. The high-end system reinforces the utility of the standard MALDI Biotyper and the high-throughput MALDI Biotyper smart.
In addition to all routine clinical FDA-approved identification assays, new fast assays (that can identify colistin resistance in gram-negative bacteria) can now be developed and confirmed on the MALDI Biotyper Sirius on the same instrument.
The new MBT sirius utilizes the proprietary smartbeam solid-state laser with a 200-Hz repetition rate and a lifetime of 500 million shots. The high-performance vacuum system facilitates a faster exchange of target plates in laboratory workflows, where multiple technicians prepare targets independently. Moreover, this system cuts downtime after service or preventive maintenance, which can be completed on the same day.
In addition, Bruker launched the MBT-STAR assays for Selective-Testing of Antibiotic Resistance for carbapenems and for cephalosporins as RUO assays to support U.S. research and validation studies for the swift identification of antibiotic resistance.
Market Prospects
Per Grand View Research, the global antibiotic resistance market size was valued at $7.81 billion in 2017. It is anticipated to witness a CAGR of 5.6% from 2018 to 2025. Hence, the launch of the MALDI Biotyper sirius is well-timed.
Recent Developments
Lately, Bruker has been investing in a few crucial developments to boost its antibiotic-resistance testing portfolio.
In April 2019, Bruker announced the launch of new assays, software and library extensions for its MALDI Biotyper, IR Biotyper and Fluorocycler XT product lines developed for microbial identification, infection control as well as molecular diagnostics of infectious diseases. For the MBTplatform, 238 new bacteria and yeast species have been incorporated in the new CE-IVD marked in-vitro diagnostics (IVD) and RUO reference libraries. This brings the number of different bacterial and fungal species that can be accurately detected with the CE-IVD marked MALDI Biotyperto 2,887. This achievement makes the MBT an almost universal and fast-growing platform for efficient microbial identification from isolates by molecular protein fingerprinting. The platform includes superior data quality and robustness, lower cost per ID as well as significantly broader identification scope than all other molecular platforms.
Price Performance
The company has outperformed the industry in the past year. The stock has rallied 66.1% compared with the industry’s 26.5% rise.
Zacks Rank and Other Key Picks
Bruker currently sports a Zacks Rank #1 (Strong Buy).
Cerner’s long-term earnings growth rate is expected to be 13.5%.
Penumbra’s long-term earnings growth rate is projected at 21.5%.
Teleflex’s long-term earnings growth rate is estimated at 13.7%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Bruker (BRKR) Launches the MALDI Biotyper Sirius System
Bruker Corporation (BRKR - Free Report) launched the new MALDI Biotyper sirius system for all previously FDA-approved assays and research-use-only (RUO) MALDI Biotyper (MBT) reference libraries at the ASM Microbe Conference 2019. These reference libraries are used for near-universal, fast and cost-efficient microbial identification from cultures in microbiology. The launch is a milestone for Bruker in the field of assay research and clinical studies for fast antibiotic-resistance testing.
More About MALDI Biotyper Sirius
The MALDI Biotyper sirius supports novel negative-ion mode assay research and clinical studies in fast antibiotic-resistance testing. The high-end system reinforces the utility of the standard MALDI Biotyper and the high-throughput MALDI Biotyper smart.
In addition to all routine clinical FDA-approved identification assays, new fast assays (that can identify colistin resistance in gram-negative bacteria) can now be developed and confirmed on the MALDI Biotyper Sirius on the same instrument.
The new MBT sirius utilizes the proprietary smartbeam solid-state laser with a 200-Hz repetition rate and a lifetime of 500 million shots. The high-performance vacuum system facilitates a faster exchange of target plates in laboratory workflows, where multiple technicians prepare targets independently. Moreover, this system cuts downtime after service or preventive maintenance, which can be completed on the same day.
In addition, Bruker launched the MBT-STAR assays for Selective-Testing of Antibiotic Resistance for carbapenems and for cephalosporins as RUO assays to support U.S. research and validation studies for the swift identification of antibiotic resistance.
Market Prospects
Per Grand View Research, the global antibiotic resistance market size was valued at $7.81 billion in 2017. It is anticipated to witness a CAGR of 5.6% from 2018 to 2025. Hence, the launch of the MALDI Biotyper sirius is well-timed.
Recent Developments
Lately, Bruker has been investing in a few crucial developments to boost its antibiotic-resistance testing portfolio.
In April 2019, Bruker announced the launch of new assays, software and library extensions for its MALDI Biotyper, IR Biotyper and Fluorocycler XT product lines developed for microbial identification, infection control as well as molecular diagnostics of infectious diseases. For the MBTplatform, 238 new bacteria and yeast species have been incorporated in the new CE-IVD marked in-vitro diagnostics (IVD) and RUO reference libraries. This brings the number of different bacterial and fungal species that can be accurately detected with the CE-IVD marked MALDI Biotyperto 2,887. This achievement makes the MBT an almost universal and fast-growing platform for efficient microbial identification from isolates by molecular protein fingerprinting. The platform includes superior data quality and robustness, lower cost per ID as well as significantly broader identification scope than all other molecular platforms.
Price Performance
The company has outperformed the industry in the past year. The stock has rallied 66.1% compared with the industry’s 26.5% rise.
Zacks Rank and Other Key Picks
Bruker currently sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the broader medical space are Cerner Corporation , Penumbra (PEN - Free Report) and Teleflex Inc (TFX - Free Report) . Each of these stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cerner’s long-term earnings growth rate is expected to be 13.5%.
Penumbra’s long-term earnings growth rate is projected at 21.5%.
Teleflex’s long-term earnings growth rate is estimated at 13.7%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>